MAREVAN TABLET 3 mg (NEW ZEALAND)

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

WARFARIN SODIUM

Available from:

GLAXOSMITHKLINE PTE LTD

ATC code:

B01AA03

Dosage:

3 mg

Pharmaceutical form:

TABLET

Composition:

WARFARIN SODIUM 3 mg

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

DOUGLAS MANUFACTURING LTD

Authorization status:

ACTIVE

Authorization date:

1995-02-02

Patient Information leaflet

 
MAREVAN™ 

WARFARIN

QUALITATIVE AND QUANTITATIVE COMPOSITION 
Warfarin sodium as 1 mg, 3 mg and 5 mg tablets.  
Marevan Tablets 1mg: Brown tablets engraved DF/M1, each tablet
containing Warfarin 
Sodium BP 1 mg.  
Marevan Tablets 3mg: Blue tablets engraved DF/M3, each tablet
containing Warfarin 
Sodium BP 3 mg  
Marevan Tablets 5mg: Pink tablets engraved DF/M5, each tablet
containing Warfarin 
Sodium BP 5 mg.  
PHARMACEUTICAL FORM 
Tablets.  
CLINICAL PARTICULARS 
INDICATIONS 

Prophylaxis of systemic embolisation in patients with rheumatic
heart disease and atrial 
fibrillation.  Prophylaxis after insertion of prosthetic heart
valves.  Prophylaxis and 
treatment of venous thrombosis and pulmonary embolism.  Transient
cerebral ischaemic 
attacks.  
DOSAGE AND ADMINISTRATION 

10 to 15 mg daily, according to age and body weight, and
adjusted with relation to the 
results of daily control tests until the desired level of
anticoagulant activity is achieved - 
usually three to six days after the initiation of treatment.  
Control tests should be made at regular intervals and
the _MAREVAN_ dosage must be 
adjusted in accordance with the results obtained.  
Concomitant heparin therapy affects the results of control tests
and should be 
discontinued at least 6 h before the first test is carried out.  
In emergencies, anticoagulant therapy should be initiated with
heparin and _MAREVAN _
together.  Where there is less urgency, as in patients disposed to
or at special risk of 
thromboembolism, anticoagulant therapy may be initiated
with _MAREVAN_ alone.  
CONTRAINDICATIONS 

−  
Pregnancy:  Oral anticoagulants should not be used
in pregnancy particularly 
because of possible teratogenicity and the risk of foetal
haemorrhage near term.  It 
is therefore suggested that heparin (which does not cross the
placenta) be used 
during the first trimester and after 37 weeks' gestation.  However,
the use of

Summary of Product characteristics

MAREVAN™
WARFARIN
QUALITATIVE AND QUANTITATIVE COMPOSITION
Warfarin sodium as 1 mg, 3 mg and 5 mg tablets.
_Warfarin sodium, 1 mg, tablet _
Each tablet contains 1 mg of warfarin sodium.
_Warfarin sodium, 3 mg, tablet _
Each tablet contains 3 mg of warfarin sodium.
_Warfarin sodium, 5 mg, tablet _
Each tablet contains 5 mg of warfarin sodium.
PHARMACEUTICAL FORM
Warfarin sodium, 1 mg, tablet
Brown round flat bevelled edge tablets engraved DF/M1
Warfarin sodium, 3 mg, tablet
Pale blue round flat bevelled edge tablets engraved DF/M3
Warfarin sodium, 5 mg, tablet
Pink round flat bevelled edge tablets engraved DF/M5
CLINICAL PARTICULARS
INDICATIONS
For:

Prophylaxis of systemic embolisation in patients with rheumatic heart
disease and
atrial fibrillation.

Prophylaxis of thromboembolism after insertion of prosthetic heart
valves.

Prophylaxis and treatment of venous thrombosis and pulmonary embolism.

Transient attacks of cerebral ischaemia.
DOSAGE AND ADMINISTRATION
For oral use.
_Adults: _
The typical induction dose is 10 mg daily for 2 days but this should
be tailored to
individual requirements. The daily maintenance dose is usually 3 to 9
mg taken at the
same time each day. The exact maintenance dose depends on the
prothrombin time or
other appropriate coagulation tests.
Control tests should be made at regular intervals and the warfarin
dosage should be
adjusted in accordance with the results obtained. Once the maintenance
dose is
established, it is rarely necessary to alter it.
In emergencies, anticoagulant therapy should be initiated with heparin
and warfarin
together.
Concomitant heparin therapy affects the results of control tests and
should be
discontinued at least 6 h before the first test is carried out.
_Children: _
Dosage for children has not been established.
_Elderly: _
As for adults, but dosage may need to be lowered.
_Renal impairment: _
Caution is advised in patients with renal impairment (see section
_Warnings and _
_Precautions_).
_Hepatic impairment: _
Caution is advised in patients